Codex Labs to present 95% SCORAD drop in open-label pediatric eczema pilot
The Silicon Valley skincare company will show an 80-child, single-arm result at a pediatric dermatology meeting, a descriptive signal rather than a controlled comparison against standard eczema care.
Executive Summary
- Codex Labs will present a pilot study of its skin barrier supplement and topical regimen in young children with eczema at a pediatric dermatology conference, reporting a severity-score reduction without steroid use.
- The result comes from an open-label, single-arm pilot with no control group, so it establishes a descriptive signal rather than a comparative efficacy finding.
- The registered trial's enrollment figure and the number of children the company says it analyzed for the poster diverge, a discrepancy that has not been reconciled.
- The finding builds on the company's own prior adult studies of the same protocol rather than adding a new mechanism to a competitive field of prescription eczema therapies.
The presentation
Codex Labs Corporation, a Silicon Valley company that develops plant-based products for inflammatory skin conditions, will present "L-Histidine Supplements Combined with Topicals in Children with Atopic Dermatitis: An Open-Label Pilot Study" as Poster POS-013 at the Society of Pediatric Dermatology's 51st Annual Meeting in Minneapolis on July 23, 2026. The pilot combined the company's Bia Skin Barrier Supplement with plant-biotech topical formulations in children ages 1 to 12 with mild to moderate atopic dermatitis, and reported an 95% reduction in SCORAD, a composite eczema severity score, after eight weeks with no topical corticosteroid use. Dr. Barbara Paldus, the company's founder and chief executive, said the study shows "what becomes possible when treatment addresses skin barrier integrity and the microbiome together". CodexCodex Labs to Present Pediatric Eczema Study Showing 95% SCORAD Reduction Without Steroids at ...Jul 2, 2026
The design
The pilot was open-label and single-arm: every child received the Bia supplement and topical regimen, with no comparator group receiving standard care or a control formulation. That design can describe a change in severity score over time in the treated group. It cannot isolate how much of that change came from the intervention versus the natural course of mild to moderate eczema in children, a population where symptoms fluctuate. The company frames the finding as building on two adult studies of the same plant-biotech protocol, published in the Journal of Integrative Dermatology in 2026, which reported up to a 99% reduction in adult SCORAD without corticosteroids. All three studies share the same open-label, uncontrolled design. CodexCodex Labs to Present Pediatric Eczema Study Showing 95% SCORAD Reduction Without Steroids at ...Jul 2, 2026
An unreconciled count
The trial behind this presentation, NCT07670676, registered as "The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With Eczema," lists an actual enrollment of 40 patients in Poland, with a primary completion date of March 31, 2026. The poster describes results from 80 children analyzed, twice the registered enrollment figure, and the gap between the two counts is not resolved. The trial's primary outcome measure on file is the Eczema Area Severity Index, a different severity instrument than the SCORAD score the company highlights in its presentation. NCT07670676The Effects of an L-histidine-Based Supplement, Eczema Topical, and Unscented Soap on Children With EczemaNCT07670676
The competitive frame
Pediatric and adult atopic dermatitis has a field of approved and late-stage prescription options, including JAK inhibitors such as upadacitinib and abrocitinib and biologics such as amlitelimab, several of which are running Phase 3 programs in children as young as two. None of those programs share Codex Labs' modality, and no direct comparator to the Bia protocol exists among registered trials in this indication. The company's protocol has not been tested against any of these standards of care, active comparator, or placebo, so the reported severity reduction cannot be benchmarked against what an approved eczema therapy delivers in a controlled setting.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.